Anavex Life Sciences Corp (AVXL)

[MycroftHolmes]

Re: Doc Analysis

Umm.. huh?

By your own analysis:

If instead 50 vs placebo and 30 mg vs placebo was the primary endpoint pre-specified endpoint then we have no data to offer an educated opinion as dose breakdown data is missing (missing for us, Missling has had it concurrent with receiving the initial analysis --- you don't not get the primary data)

and

So I put the likelihood at near zero. I do think you came up with possibilities that together add up to the 1-2% chance that I give for AA

So you give 1-2% chance that Anavex both 1) pre-specified a primary endpoint of 50mg vs placebo and that the 2) resulting benefit (which we don't have but know the overall mean is high) is sufficient for Accelerated Approval?

I do appreciate your analysis on this board, but I don't think I am being a Polly Anna when I say that this assessment seems unnecessarily pessimistic.

Cheers

Mycroft